{
    "nct_id": "NCT04775485",
    "official_title": "FIREFLY-1: A Phase 2, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients With RAF-Altered, Recurrent or Progressive Low-Grade Glioma and Advanced Solid Tumors",
    "inclusion_criteria": "* Low Grade Glioma & Low-Grade Glioma Extension: a relapsed or progressive LGG with documented known activating BRAF alteration.\n* Advanced Solid Tumor: locally advanced or metastatic solid tumor with documented known or expected to be activating RAF fusion.\n* Participants must have histopathologic verification of malignancy at either original diagnosis or relapse.\n* Must have received at least one line of prior systemic therapy and have documented evidence of radiographic progression.\n* Must have at least 1 measurable lesion as defined by RANO (Arms 1 & 2) or RECIST v1.1 (Arm 3) criteria\nHealthy volunteers allowed\nMust have minimum age of 6 Months\nMust have maximum age of 25 Years",
    "exclusion_criteria": "* Participant's tumor has additional previously-known activating molecular alterations.\n* Participant has symptoms of without radiographically recurrent or radiographically progressive disease.\n* Known or suspected diagnosis of neurofibromatosis type 1 (NF-1) via genetic testing or current diagnostic criteria.\n\nOther inclusion/exclusion criteria as stipulated by protocol may apply",
    "miscellaneous_criteria": ""
}